Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.02 EUR | 0.00% | +1.00% | +7.16% |
14/06 | Finland's Biohit Names Chief Technology Officer | MT |
15/04 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 27.61 | 23.62 | 28.49 | 30.65 | - | - |
Enterprise Value (EV) 1 | 27.61 | 23.62 | 28.49 | 22.25 | 20.65 | 30.65 |
P/E ratio | -18.4 x | 39.3 x | 15.7 x | 15.5 x | 15.5 x | 13.5 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | 2.17 x | 2 x | 1.76 x | 1.56 x |
EV / Revenue | - | - | 2.17 x | 1.45 x | 1.19 x | 1.56 x |
EV / EBITDA | - | - | 12.9 x | 9.67 x | 7.38 x | 9.01 x |
EV / FCF | - | - | - | 6.18 x | 12.9 x | 18 x |
FCF Yield | - | - | - | 16.2% | 7.75% | 5.55% |
Price to Book | - | - | - | 2.66 x | 2.27 x | - |
Nbr of stocks (in thousands) | 15,046 | 15,046 | 15,114 | 15,174 | - | - |
Reference price 2 | 1.835 | 1.570 | 1.885 | 2.020 | 2.020 | 2.020 |
Announcement Date | 16/02/22 | 15/02/23 | 14/02/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | 13.1 | 15.3 | 17.4 | 19.7 |
EBITDA 1 | - | - | 2.2 | 2.3 | 2.8 | 3.4 |
EBIT 1 | - | - | 1.8 | 1.9 | 2.5 | 2.8 |
Operating Margin | - | - | 13.74% | 12.42% | 14.37% | 14.21% |
Earnings before Tax (EBT) 1 | - | - | 2.2 | 2.1 | 2.5 | 2.8 |
Net income 1 | -1.5 | 0.6 | 1.9 | 1.9 | 2 | 2.3 |
Net margin | - | - | 14.5% | 12.42% | 11.49% | 11.68% |
EPS 2 | -0.1000 | 0.0400 | 0.1200 | 0.1300 | 0.1300 | 0.1500 |
Free Cash Flow 1 | - | - | - | 3.6 | 1.6 | 1.7 |
FCF margin | - | - | - | 23.53% | 9.2% | 8.63% |
FCF Conversion (EBITDA) | - | - | - | 156.52% | 57.14% | 50% |
FCF Conversion (Net income) | - | - | - | 189.47% | 80% | 73.91% |
Dividend per Share 2 | - | - | - | - | - | - |
Announcement Date | 16/02/22 | 15/02/23 | 14/02/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|---|
Net sales 1 | 6.5 | 6.6 | 7.6 | 7.7 | 8.6 | 8.8 |
EBITDA 1 | 1.7 | 0.5 | 1.2 | 1.1 | 1.3 | 1.2 |
EBIT 1 | 1.5 | 0.3 | 1 | 0.9 | 1.3 | 1.2 |
Operating Margin | 23.08% | 4.55% | 13.16% | 11.69% | 15.12% | 13.64% |
Earnings before Tax (EBT) 1 | 1.7 | 0.5 | 1.1 | 1 | 1.3 | 1.2 |
Net income 1 | 1.4 | 0.5 | 1 | 0.9 | 1.3 | 1.2 |
Net margin | 21.54% | 7.58% | 13.16% | 11.69% | 15.12% | 13.64% |
EPS 2 | 0.0900 | 0.0300 | 0.0600 | 0.0600 | 0.0900 | 0.0800 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 09/08/23 | 14/02/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | 8.4 | 10 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | 3.6 | 1.6 | 1.7 |
ROE (net income / shareholders' equity) | - | - | - | 18.2% | 15.8% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | 0.7600 | 0.8900 | - |
Cash Flow per Share 2 | - | - | - | 0.2900 | 0.1600 | - |
Capex 1 | - | - | - | 0.7 | 0.7 | 0.8 |
Capex / Sales | - | - | - | 4.58% | 4.02% | 4.06% |
Announcement Date | 16/02/22 | 15/02/23 | 14/02/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.16% | 3.28Cr | |
+2.11% | 737.42Cr | |
-12.41% | 429.22Cr | |
+1.31% | 317.84Cr | |
+17.42% | 230.8Cr | |
+7.78% | 94Cr | |
-39.11% | 93Cr | |
-57.14% | 68Cr | |
-28.72% | 63Cr | |
-36.34% | 62Cr |
- Stock Market
- Equities
- BIOBV Stock
- Financials Biohit Oyj